Analysts are questioning Alnylam Pharmaceuticals' valuation as its RNAi pipeline develops.
Alnylam Pharmaceuticals is under scrutiny as analysts suggest the company may be undervalued based on its RNAi pipeline. This assessment comes amid a challenging trading environment for the stock, which has seen a significant decline of 43.89% year-to-date. The stock closed at US$231.26, reflecting a slight increase of 0.05% on the day, yet down 2.88% over the past week and 13.68% over the past month.
Investor takeaway: Investors should consider how Alnylam's valuation aligns with its future potential as indicated by its pipeline.
Advertisement
Alnylam Pharmaceuticals Inc
ALNY.US
ALNY.US
Alnylam Pharmaceuticals Inc
WealthAwesomeMarket cap
$30.03B
P/E
37.8x
52W high
$495.55
52W low
$197.81
1W change
-2.88%
Beta
0.27
Analyst Price Targets
Based on 29 analysts covering ALNY · as of Oct 5, 2026
Wall Street analysts forecast ALNY stock price to rise 65.3% over the next 12 months.
Consensus
Buy4.31 / 5.00
Avg. Target
C$371.12
+65.3% Upside
Current Price
C$224.53
Last close
Analyst Breakdown (29 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ALNY's historical volatility
30-Day Vol
45.9%
Annualized
90-Day Vol
70.8%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$187.81
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$211.56 | C$180.59 – C$247.82 |
| 60 trading days | C$199.33 | C$159.36 – C$249.32 |
| 90 trading days | C$187.81 | C$142.79 – C$247.03 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Last Close at US$231.26 with 459,021 Shares Traded
The recent trading volume was 1.32 times higher than the 20-day average, indicating increased investor interest despite a struggling stock price.
Bull case
The company's RNAi pipeline has the potential to drive significant growth in the future, suggesting that its current valuation may not fully reflect its worth.
Bear case
Market pressures and the stock's year-to-date decline raise concerns about whether the company can sustain its growth prospects.
Analysts Highlight Potential Undervaluation
Advertisement
Recent reports indicate that analysts believe Alnylam Pharmaceuticals is undervalued when considering its RNA interference (RNAi) pipeline. Currently, the stock is trading at a P/E ratio of 37.78, which might not capture the potential of its innovative therapies. This valuation contrasts with the average analyst target of US$371.12, suggesting a possible upside of about 60.5% from the current price. The market capitalization stands at around US$30.03 billion.
Current Stock Performance Overview
Alnylam's stock closed at US$231.26, showing a slight increase of 0.05% on the day. Over the past week, the stock has decreased by 2.88%, while it has seen a more substantial decline of 13.68% in the last month. The stock is currently trading at 96.4% of its 52-week range, which spans from US$197.81 to US$495.55. Volume for the day reached 459,021 shares, which is 1.32 times the 20-day average volume of 1,333,555 shares, suggesting heightened trading activity.
What’s Next for Alnylam Pharmaceuticals?
Investors will be closely watching how Alnylam's pipeline developments progress and whether they can translate into improved financial performance. The stock is currently below its 50-day moving average of US$239.36 and its 200-day moving average of US$301.18, indicating a bearish trend. Future updates on clinical trials and pipeline advancements will be crucial in determining the company's ability to support its valuation. The profit margin of the company stands at 16.1%, and its return on equity (ROE) is notably high at 96.6%.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
